The emerging agenda of stratified medicine in neurology

Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer’s Coordinating Centre

(2013) Jon B. Toledo et al.   BRAIN

Chaperone therapy update: Fabry disease, GM1-gangliosidosis and Gaucher disease

(2013) Yoshiyuki Suzuki   BRAIN & DEVELOPMENT

Genome-Wide Association Studies, Alzheimer Disease, and Understudied Populations

(2013) Robert L. Nussbaum   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Association of smoking with risk of multiple sclerosis: a population-based study

(2013) Sreeram V. Ramagopalan et al.   JOURNAL OF NEUROLOGY

Brain Microstructure Reveals Early Abnormalities more than Two Years prior to Clinical Progression from Mild Cognitive Impairment to Alzheimer's Disease

(2013) G. Douaud et al.   JOURNAL OF NEUROSCIENCE

Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers

(2013) Clifford R Jack et al.   LANCET NEUROLOGY

De novo mutations in epileptic encephalopathies

(2013) et al.   NATURE

Defining and scoring response to IFN-β in multiple sclerosis

(2013) Maria Pia Sormani et al.   Nature Reviews Neurology

Cost-effectiveness of HLA-B*1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore

(2013) S.-I. Hung et al.   NEUROLOGY

(De)Personalized Medicine

(2013) R. I. Horwitz et al.   SCIENCE

Impacts of massively parallel sequencing for genetic diagnosis of neuromuscular disorders

(2012) Nasim Vasli et al.   ACTA NEUROPATHOLOGICA

Next generation sequencing for molecular diagnosis of neuromuscular diseases

(2012) Nasim Vasli et al.   ACTA NEUROPATHOLOGICA

Predictors of long-term outcome in multiple sclerosis patients treated with interferon beta

(2012) Robert A. Bermel et al.   ANNALS OF NEUROLOGY

Personalized medicine in multiple sclerosis: hope or reality?

(2012) Tobias Derfuss   BMC Medicine

HLA Genotype and Carbamazepine-Induced Cutaneous Adverse Drug Reactions: A Systematic Review

(2012) V L Yip et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Web-Based Patient-Reported Outcomes in Drug Safety and Risk Management

(2012) Anjan K. Banerjee et al.   DRUG SAFETY

Recent advances in the genetics and immunology of Stevens-Johnson syndrome and toxic epidermal necrosis

(2012) Wen-Hung Chung et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

Extensive innate immune gene activation accompanies brain aging, increasing vulnerability to cognitive decline and neurodegeneration: a microarray study

(2012) David H Cribbs et al.   Journal of Neuroinflammation

Environmental factors and their regulation of immunity in multiple sclerosis

(2012) Marcus W. Koch et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control study

(2012) Jennifer L Whitwell et al.   LANCET NEUROLOGY

Increased PK11195 PET binding in the cortex of patients with MS correlates with disability

(2012) M. Politis et al.   NEUROLOGY

Vitamin D in MS: A vitamin for 4 seasons

(2012) A. Ascherio et al.   NEUROLOGY

Serum IL-17F does not predict poor response to IM IFN -1a in relapsing-remitting MS

(2012) S. E. Bushnell et al.   NEUROLOGY

Predicting outcome of IV thrombolysis-treated ischemic stroke patients: The DRAGON score

(2012) D. Strbian et al.   NEUROLOGY

Cost-effectiveness of HLA-B*1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore

(2012) D. Dong et al.   NEUROLOGY

Safety and pharmacodynamic effects of a pharmacological chaperone on α-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies

(2012) Dominique P Germain et al.   Orphanet Journal of Rare Diseases

Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Clifford R. Jack et al.   Alzheimers & Dementia

The Alzheimer’s Disease Neuroimaging Initiative: A review of papers published since its inception

(2011) Michael W. Weiner et al.   Alzheimers & Dementia

Pharmacogenomics in neurology: Current state and future steps

(2011) Andrew Chan et al.   ANNALS OF NEUROLOGY

Using Pharmacogenetics in Real Time to Guide Warfarin Initiation

(2011) John F. Carlquist et al.   CIRCULATION

Molecular genetics of Dravet syndrome

(2011) PETER DE JONGHE   DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY

Clinical comparability of the new antiepileptic drugs in refractory partial epilepsy: A systematic review and meta-analysis

(2011) João Costa et al.   EPILEPSIA

Newly diagnosed epilepsy and pharmacogenomics research: A step in the right direction?

(2011) Michael R. Johnson et al.   EPILEPSY & BEHAVIOR

Twenty years of Alzheimer’s disease-causing mutations

(2011) Alison Goate et al.   JOURNAL OF NEUROCHEMISTRY

The cellular pathology of lysosomal diseases

(2011) Timothy M Cox et al.   JOURNAL OF PATHOLOGY

Exon-skipping therapy for Duchenne muscular dystrophy

(2011) Akinori Nakamura et al.   LANCET

Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease

(2011) Paul Hollingworth et al.   NATURE GENETICS

Predictive, personalized, preventive, participatory (P4) cancer medicine

(2011) Leroy Hood et al.   Nature Reviews Clinical Oncology

Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia

(2011) William E. Klunk   NEUROBIOLOGY OF AGING

Magnetic resonance spectroscopy,  -amyloid load, and cognition in a population-based sample of cognitively normal older adults

(2011) K. Kantarci et al.   NEUROLOGY

Cognition and beta-amyloid in preclinical Alzheimer's disease: Data from the AIBL study

(2011) Kerryn E. Pike et al.   NEUROPSYCHOLOGIA

HLA-A*3101 and Carbamazepine-Induced Hypersensitivity Reactions in Europeans

(2011) Mark McCormack et al.   NEW ENGLAND JOURNAL OF MEDICINE

Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab

(2010) Martin Gunnarsson et al.   ANNALS OF NEUROLOGY

A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation

(2010) Ron Pisters et al.   CHEST

Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population

(2010) Takeshi Ozeki et al.   HUMAN MOLECULAR GENETICS

Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis

(2010) M. Axelsson et al.   JOURNAL OF NEUROLOGY

Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis

(2010) Chris H Polman et al.   LANCET NEUROLOGY

Relationship between brain MRI lesion load and short-term disease evolution in non-disabling MS: a large-scale, multicentre study

(2010) Marco Rovaris et al.   Multiple Sclerosis Journal

Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course

(2010) Mohsen Khademi et al.   Multiple Sclerosis Journal

Personalized medicine in oncology: the future is now

(2010) Richard L. Schilsky   NATURE REVIEWS DRUG DISCOVERY

The use of PET in Alzheimer disease

(2010) Agneta Nordberg et al.   Nature Reviews Neurology

Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis

(2010) R. A. Marrie et al.   NEUROLOGY

Comparing predictors of conversion and decline in mild cognitive impairment

(2010) S. M. Landau et al.   NEUROLOGY

MRI criteria for MS in patients with clinically isolated syndromes

(2010) X. Montalban et al.   NEUROLOGY

The Path to Personalized Medicine

(2010) Margaret A. Hamburg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Common risk allele in aromatic antiepileptic-drug induced Stevens–Johnson syndrome and toxic epidermal necrolysis in Han Chinese

(2010) Shuen-Iu Hung et al.   PHARMACOGENOMICS

Biomarkers for Alzheimer's disease therapeutic trials

(2010) Harald Hampel et al.   PROGRESS IN NEUROBIOLOGY

Personalised Genetic Intervention for Duchenne Muscular Dystrophy: Antisense Oligomers and Exon Skipping

(2010) Chalermchai Mitrpant et al.   Current Molecular Pharmacology

Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: A meta-analytic approach

(2009) Maria Pia Sormani et al.   ANNALS OF NEUROLOGY

Preferential recruitment of interferon-γ-expressing TH17 cells in multiple sclerosis

(2009) Hania Kebir et al.   ANNALS OF NEUROLOGY

Elevated Epstein-Barr virus-encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosis

(2009) Jan D. Lünemann et al.   ANNALS OF NEUROLOGY

Imaging Biomarkers in Alzheimer's Disease

(2009) Natalie S. Ryan et al.   Annals of the New York Academy of Sciences

Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach

(2009) Gregory Y.H. Lip et al.   CHEST

Genetic basis for idiosyncratic reactions to antiepileptic drugs

(2009) Diego Franciotta et al.   CURRENT OPINION IN NEUROLOGY

The Alberta Stroke Program Early CT Score in Clinical Practice: What have We Learned?

(2009) V. Puetz et al.   International Journal of Stroke

Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease

(2009) Denise Harold et al.   NATURE GENETICS

The microeconomics of personalized medicine: today's challenge and tomorrow's promise

(2009) Jerel C. Davis et al.   NATURE REVIEWS DRUG DISCOVERY

Predicting responders to therapies for multiple sclerosis

(2009) Jordi Río et al.   Nature Reviews Neurology

Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI

(2009) Susan M. Landau et al.   NEUROBIOLOGY OF AGING

A reassessment of the plateauing relationship between T2 lesion load and disability in MS

(2009) M. P. Sormani et al.   NEUROLOGY

Absence of MxA induction by interferon   in patients with MS reflects complete loss of bioactivity

(2009) D. Hesse et al.   NEUROLOGY

Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI

(2009) R. A. Farrell et al.   NEUROLOGY

Number Needed to Treat to Benefit and to Harm for Intravenous Tissue Plasminogen Activator Therapy in the 3- to 4.5-Hour Window

(2009) Jeffrey L. Saver et al.   STROKE

Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis

(2008) L. K. Fisniku et al.   BRAIN

Diagnosis and treatment of dementia: 2. Diagnosis

(2008) H. H. Feldman et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

A Risk Score to Predict Intracranial Hemorrhage After Recombinant Tissue Plasminogen Activator for Acute Ischemic Stroke

(2008) Brett Cucchiara et al.   Journal of Stroke & Cerebrovascular Diseases

Translation towards personalized medicine in Multiple Sclerosis

(2008) Ariel Miller et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

RNA-Seq: a revolutionary tool for transcriptomics

(2008) Zhong Wang et al.   NATURE REVIEWS GENETICS

The HAT Score: A simple grading scale for predicting hemorrhage after thrombolysis

(2008) M. Lou et al.   NEUROLOGY

Comorbidity delays diagnosis and increases disability at diagnosis in MS

(2008) R. A. Marrie et al.   NEUROLOGY

Carbamazepine,HLA-B*1502and risk of Stevens–Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations

(2008) P Brent Ferrell et al.   PHARMACOGENOMICS

Pharmacogenomics of IFN-β in multiple sclerosis: towards a personalized medicine approach

(2008) Saskia Vosslamber et al.   PHARMACOGENOMICS